Abivax Accounts Payable

Abivax (ABVX) currently reports a accounts payable of $18M as of June 2026. That compares with $57M in the prior-year period — down 68.2% year over year. Use the charts on this page to explore Abivax's accounts payable history and peer comparisons.

Abivax's accounts payable decreased from $57M to $18M — a 68.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abivax reported $18M in accounts payable as of June 2026. That compares with $57M in the prior-year period — down 68.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abivax, and consider following ABVX for alerts when major investors trade the stock.

Abivax is classified in the Healthcare sector. On accounts payable, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABVX with unrelated industries.